← Leaderboards
Ken J McCormack
Arisan Therapeutics, Inc.
$1,995,261
Attributed
$2,295,261
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $600K · FY2011–19$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,295,261 · 5
By mechanism
R43$2,295,261 · 5
Top collaborators
- Michael Bruno Plewe2 shared
Most similar at Arisan Therapeutics, Inc.
Same institution · by research overlap
- Gregory William Henkel$14,774,797
- Michael Bruno Plewe$1,050,000
Others in their field
Top investigators on “Antiviral Agents”
- Constance Ann Benson · University Of California, San Diego$209,152,068
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$120,325,769
- Judith S. Currier · University Of California Los Angeles$102,391,456
- Beth Baseler · Leidos Biomedical Research, Inc.$83,440,795
- Sharon A Nachman · Johns Hopkins University$77,262,665
- John Damon Chodera · Sloan-Kettering Inst Can Research$58,660,403
Research focus
Antiviral AgentsNational Institute Of Allergy And Infectious DiseaseInhibitor/AntagonistProphylactic TreatmentPropertyInfectionViralCytotoxicitySeriesPharmaceutical PreparationsExhibitsLiver MicrosomesPharmaceutical ChemistryToxic EffectBaseAreaDisease OutbreaksProphylacticMutationLeadIn VitroGlycoproteinsCategoriesCells
Grant awards (8)
Optimization of Ebola Virus Entry Inhibitors$300,000
R43 · FY2019 · AI · contact PI
Optimization of Ebola Virus Entry Inhibitors$350,000
R43 · FY2018 · AI · contact PI
Optimization of Arenavirus Antivirals$300,000
R43 · FY2015 · AI
Ebola Virus Entry Inhibitors$300,000
R43 · FY2015 · AI · contact PI
Optimization of Arenavirus Antivirals$300,000
R43 · FY2014 · AI
OPTIMIZATION OF NOVEL INFLUENZA M2 CHANNEL INHIBITORS$300,000
R43 · FY2013 · AI · contact PI
Development of novel broad-spectrum influenza A inhibitors$222,059
R43 · FY2012 · AI · contact PI
Development of novel broad-spectrum influenza A inhibitors$223,202
R43 · FY2011 · AI · contact PI